載入中
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
前收盤價
US$0.2113
−US$0.0081 · -3.69%
盤中時間採用ET。市場資料可能有所延遲。
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
日內區間
目前US$0.2113
52週區間
目前US$0.2113
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
57
合理估值
情緒
51
多空交錯
風險
73
高風險
動能
21
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
日內區間
目前US$0.2113
52週區間
目前US$0.2113
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 172.74萬 USD | 123.35萬 USD | 77.53萬 USD | 30.64萬 USD | 9萬 USD |
| 毛利 | 172.74萬 USD | 123.35萬 USD | 77.53萬 USD | 30.64萬 USD | 9萬 USD |
| 研究與開發 | 1008.13萬 USD | 1440.65萬 USD | 1955.15萬 USD | 1533.3萬 USD | 1302.24萬 USD |
| 銷售、一般及管理費用 | 1338.47萬 USD | 1363.96萬 USD | 1691.94萬 USD | 1640.47萬 USD | 1482.63萬 USD |
| 營業費用 | 2294.94萬 USD | 2825.85萬 USD | 3676.3萬 USD | 3208.65萬 USD | 2842.31萬 USD |
| 利息收入 | 600 USD | 9947 USD | 9.33萬 USD | 12.53萬 USD | 2734 USD |
| 利息支出 | 248.93萬 USD | 34.04萬 USD | 22.16萬 USD | 17.31萬 USD | 15.58萬 USD |
| 折舊和攤銷 | 121.64萬 USD | 133.89萬 USD | 141.33萬 USD | 118.99萬 USD | 114.52萬 USD |
| 營業利益 | −2122.21萬 USD | −2702.5萬 USD | −3598.77萬 USD | −3178.01萬 USD | −2833.31萬 USD |
| 淨利 | −2335.7萬 USD | −2696.78萬 USD | −3531.91萬 USD | −3026.88萬 USD | −2681.47萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年4月28日 | 1:20 | — | — |
已生效 2026年4月28日
1:20
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
